172 related articles for article (PubMed ID: 3161047)
1. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
2. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
3. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
Peters WG; Willemze R; Colly LP
Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
[TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Hines JD; Oken MM; Mazza JJ; Keller AM; Streeter RR; Glick JH
J Clin Oncol; 1984 Jun; 2(6):545-9. PubMed ID: 6233399
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Marit G; David B; Reiffers J; Broustet A
Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
[TBL] [Abstract][Full Text] [Related]
6. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Willemze R; Peters WG; van Hennik MB; Fibbe WE; Kootte AM; van Berkel M; Lie R; Rodenburg CJ; Veltkamp JJ
Scand J Haematol; 1985 Jan; 34(1):83-7. PubMed ID: 3855571
[TBL] [Abstract][Full Text] [Related]
7. A phase I and II study of m-AMSA in acute leukaemia.
Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Dhaliwal HS; Shannon MS; Barnett MJ; Prentice HG; Bragman K; Malpas JS; Lister TA
Cancer Chemother Pharmacol; 1986; 18(1):59-62. PubMed ID: 3463435
[TBL] [Abstract][Full Text] [Related]
10. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G
Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729
[TBL] [Abstract][Full Text] [Related]
12. High dose cytarabine: a review.
Bolwell BJ; Cassileth PA; Gale RP
Leukemia; 1988 May; 2(5):253-60. PubMed ID: 3287015
[TBL] [Abstract][Full Text] [Related]
13. Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
Peters WG; Willemze R; Colly LP
Scand J Haematol Suppl; 1986; 44():7-16. PubMed ID: 3515513
[No Abstract] [Full Text] [Related]
14. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
[TBL] [Abstract][Full Text] [Related]
15. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
[TBL] [Abstract][Full Text] [Related]
16. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Tschopp L; von Fliedner VE; Sauter C; Maurice P; Gratwohl A; Fopp M; Cavalli F
J Clin Oncol; 1986 Mar; 4(3):318-24. PubMed ID: 3456425
[TBL] [Abstract][Full Text] [Related]
18. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Arlin ZA; Ahmed T; Mittelman A; Feldman E; Mehta R; Weinstein P; Rieber E; Sullivan P; Baskind P
J Clin Oncol; 1987 Mar; 5(3):371-5. PubMed ID: 3546613
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
[No Abstract] [Full Text] [Related]
20. [High-dose cytosine arabinoside in the treatment of recurrent or acute refractory myeloid leukemias].
Brudler O; Heil G; Kurrle E
Onkologie; 1985 Feb; 8(1):39-40, 42-3. PubMed ID: 3885119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
